Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17
HOS-132263 · Präparat HOS-097208
(Induction of P-gp) HMG-CoA REDUCTASE INHIBITORS Rosuvastating ↑ Rosuvastatin Co-administration of Harvoni with rosuvastatin may significantly increase the concentration of (Inhibition of drug rosuvastatin (several fold-increase in AUC) which transporters OATP and is associated with increased risk of myopathy, BCRP) including rhabdomyolysis. Co-administration of Harvoni with rosuvastatin is contraindicated (see section 4.3). Pravastating ↑ Pravastatin Co-administration of Harvoni with pravastatin may significantly increase the concentration of pravastatin which is associated with increased risk of myopathy. Clinical and biochemical control is recommended in these patients and a dose adjustment may be needed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 80c33e016e53fd2e4e6840996e3c36fc6b68fe8f03783c3149d8a7cd296f16da · Zeichen 31765–33202 im Abschnitt